Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Colorcon
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Last Updated: May 28, 2022

Investigational Drug Information for VTP-194204


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug VTP-194204?

VTP-194204 is an investigational drug.

There have been 18 clinical trials for VTP-194204. The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Eczema. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.

There are one hundred and fourteen US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for VTP-194204
TitleSponsorPhase
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyICON plcPhase 3
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyMedpace, Inc.Phase 3
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyPrimeVigilancePhase 3

See all VTP-194204 clinical trials

Clinical Trial Summary for VTP-194204

Top disease conditions for VTP-194204
Top clinical trial sponsors for VTP-194204

See all VTP-194204 clinical trials

US Patents for VTP-194204

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VTP-194204 See Plans and Pricing Autoimmune disorder treatment using RXR agonists lo Therapeutics, Inc. (Santa Ana, CA) See Plans and Pricing
VTP-194204 See Plans and Pricing Treatment of cancer with specific RXR agonists Io Therapeutics, Inc. (Santa Ana, CA) See Plans and Pricing
VTP-194204 See Plans and Pricing DISC-1 pathway activators in the control of neurogenesis Massachusetts Institute of Technology (Cambridge, MA) The General Hospital Corporation (Boston, MA) See Plans and Pricing
VTP-194204 See Plans and Pricing Treatment of cancer with specific RXR agonists IO Therapeutics, Inc. (Santa Ana, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VTP-194204

Drugname Country Document Number Estimated Expiration Related US Patent
VTP-194204 Australia AU2012352149 2031-12-13 See Plans and Pricing
VTP-194204 Australia AU2017210644 2031-12-13 See Plans and Pricing
VTP-194204 Canada CA2858882 2031-12-13 See Plans and Pricing
VTP-194204 China CN104114171 2031-12-13 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Colorcon
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.